Leukotriene D4 is a lipid-derived inflammatory signaling hormone involved in airway constriction, vascular permeability regulation, mucus secretion, and inflammatory communication. LTD4 belongs to the cysteinyl leukotriene family and functions as one of the most potent endogenous mediators of bronchial smooth muscle contraction. Through these actions, LTD4 participates in respiratory immune responses, mucosal signaling, and coordination of inflammatory adaptation within airway tissues.
The hormone contributes to narrowing of bronchial airways, increased mucus production, tissue edema, and vascular permeability changes. LTD4 also influences eosinophil activity, endothelial signaling, and communication between inflammatory cells within respiratory environments. Because of its strong effects on airway smooth muscle, LTD4 is an important mediator linking inflammatory activation with respiratory physiological responses.
LTD4 is synthesized from arachidonic acid through the lipoxygenase pathway. Phospholipase A2 releases arachidonic acid from membrane phospholipids, after which five-lipoxygenase converts it into leukotriene intermediates. Leukotriene C4 is subsequently metabolized extracellularly into leukotriene D4 through sequential enzymatic processing.
Production occurs mainly in mast cells, eosinophils, basophils, macrophages, and additional inflammatory cell populations. Synthesis rises rapidly during allergic stimulation, inflammatory signaling, oxidative stress, and immune activation. Because leukotrienes are synthesized on demand rather than stored, LTD4 production closely reflects real-time inflammatory activity within tissues.
LTD4 synthesis is regulated by cytokine signaling, phospholipase activation, calcium-dependent immune-cell stimulation, oxidative stress pathways, and inflammatory receptor activation. Mast-cell degranulation and eosinophil activation strongly increase cysteinyl leukotriene production during airway inflammatory responses.
LTD4 acts mainly through cysteinyl leukotriene receptors located on airway smooth muscle, vascular tissue, inflammatory cells, and mucosal structures. Receptor activation stimulates calcium signaling pathways, smooth muscle contraction, vascular leakage, mucus secretion, and inflammatory amplification. Enzymatic degradation pathways gradually convert LTD4 into downstream metabolites that help limit signaling duration. Through these integrated lipid-signaling systems, LTD4 coordinates airway responsiveness, inflammatory communication, mucosal adaptation, and respiratory immune signaling.
LTD₄ is a lipid signaling mediator driving smooth muscle contraction and vascular permeability during inflammatory responses.
